Rafferty Asset Management Portfolio holdings
AUM
$30.3B
1-Year Return
18.89%
This Quarter Return
+10.63%
1 Year Return
+18.89%
3 Year Return
+101.02%
5 Year Return
+164.75%
10 Year Return
+314.44%
AUM
$26.8B
AUM Growth
+$3.09B
(+13%)
Cap. Flow
+$1.27B
Cap. Flow
% of AUM
4.74%
Top 10 Holdings %
Top 10 Hldgs %
40.07%
Holding
1,108
New
38
Increased
406
Reduced
634
Closed
28
Top Buys
| 1 |
Intel
INTC
|
+$208M |
| 2 |
Microchip Technology
MCHP
|
+$134M |
| 3 |
Qualcomm
QCOM
|
+$122M |
| 4 |
Analog Devices
ADI
|
+$122M |
| 5 |
Micron Technology
MU
|
+$113M |
Top Sells
| 1 |
iShares Russell 2000 ETF
IWM
|
+$326M |
| 2 |
NVIDIA
NVDA
|
+$116M |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$78.6M |
| 4 |
iShares China Large-Cap ETF
FXI
|
+$72.7M |
| 5 |
KraneShares CSI China Internet ETF
KWEB
|
+$36.4M |
Sector Composition
| 1 | Technology | 47.46% |
| 2 | Financials | 9.33% |
| 3 | Healthcare | 6.2% |
| 4 | Consumer Discretionary | 3.62% |
| 5 | Energy | 2.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Altimmune
ALT
$320M
| $8.99M | 0.03% |
+882,628
| New | +$8.99M |
|
302
Vericel Corp
VCEL
$1.55B
| $8.97M | 0.03% |
172,363
+66,549
| +63% | +$3.46M |
|
303
Insmed
INSM
$30.5B
| $8.94M | 0.03% |
329,635
+8,548
| +3% | +$232K |
|
304
Halozyme
HALO
$8.87B
| $8.94M | 0.03% |
219,752
-4,972
| -2% | -$202K |
|
305
Wintrust Financial
WTFC
$9.23B
| $8.93M | 0.03% |
85,510
-1,783
| -2% | -$186K |
|
306
Denali Therapeutics
DNLI
$2.15B
| $8.92M | 0.03% |
434,909
+112,936
| +35% | +$2.32M |
|
307
Intellia Therapeutics
NTLA
$1.22B
| $8.9M | 0.03% |
323,561
-5,437
| -2% | -$150K |
|
308
Keysight
KEYS
$29.1B
| $8.9M | 0.03% |
56,916
+1,410
| +3% | +$220K |
|
309
Deere & Co
DE
$129B
| $8.89M | 0.03% |
21,652
-814
| -4% | -$334K |
|
310
Syndax Pharmaceuticals
SNDX
$1.37B
| $8.88M | 0.03% |
373,238
-30,143
| -7% | -$717K |
|
311
Recursion Pharmaceuticals
RXRX
$1.99B
| $8.88M | 0.03% |
890,239
-199,934
| -18% | -$1.99M |
|
312
Ironwood Pharmaceuticals
IRWD
$188M
| $8.87M | 0.03% |
1,017,819
+316,049
| +45% | +$2.75M |
|
313
Rocket Pharmaceuticals
RCKT
$344M
| $8.86M | 0.03% |
329,043
+120,538
| +58% | +$3.25M |
|
|
SWTX
314
DELISTED
SpringWorks Therapeutics
SWTX
| $8.84M | 0.03% |
179,566
+35,219
| +24% | +$1.73M |
|
315
IDEAYA Biosciences
IDYA
$2.16B
| $8.83M | 0.03% |
201,291
+7,935
| +4% | +$348K |
|
316
Arcellx
ACLX
$3.9B
| $8.82M | 0.03% |
126,751
+14,799
| +13% | +$1.03M |
|
317
Amicus Therapeutics
FOLD
$2.44B
| $8.78M | 0.03% |
745,574
-49,777
| -6% | -$586K |
|
318
Apellis Pharmaceuticals
APLS
$3.31B
| $8.75M | 0.03% |
148,801
+5,683
| +4% | +$334K |
|
319
United Therapeutics
UTHR
$18B
| $8.67M | 0.03% |
37,730
+584
| +2% | +$134K |
|
320
Dynavax Technologies
DVAX
$1.14B
| $8.66M | 0.03% |
697,907
+157,588
| +29% | +$1.96M |
|
321
Iovance Biotherapeutics
IOVA
$836M
| $8.66M | 0.03% |
584,111
-663,404
| -53% | -$9.83M |
|
322
Biohaven
BHVN
$1.48B
| $8.65M | 0.03% |
158,192
-113,385
| -42% | -$6.2M |
|
323
Vaxcyte
PCVX
$4.14B
| $8.62M | 0.03% |
126,164
-32,249
| -20% | -$2.2M |
|
324
HP
HPQ
$26.7B
| $8.59M | 0.03% |
284,145
+12,295
| +5% | +$372K |
|
325
Duke Energy
DUK
$94.2B
| $8.58M | 0.03% |
88,724
+2,745
| +3% | +$265K |
|